Trending...
- University of Phoenix College of Doctoral Studies Releases Latest Edition of Its Phoenix ScholarTM Academic Journal Highlighting Research Based on Career Optimism Index® Study of the University's Career Institute®
- Axon Names Brittany Bagley as New Chief Financial Officer and Chief Business Officer
- Mesa: Adaptive Program Participants Heading to Camp and the Lake
PHOENIX, Dec. 3, 2021 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (the "Company") (NASDAQ: CELZ), a commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics, today announced the pricing of the underwritten public offering of 3,875,000 shares of common stock and accompanying warrants to purchase up to 3,875,000 shares of common stock at a combined public offering price of $4.13. The warrants have a per share exercise price of $4.13, are exercisable immediately, and expire five years from the date of issuance. The aggregate gross proceeds from the offering are expected to total approximately $16 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company and without giving effect to proceeds from any subsequent exercise of warrants.
As a result of the offering, the Company's common stock will become listed on the Nasdaq Capital Market and will trade under the ticker symbol "CELZ" beginning December 3, 2021. The offering is expected to close on or about December 7, 2021, subject to customary closing conditions. In addition, the Company has granted to the underwriters of the offering a 45-day option to purchase up to 581,250 additional shares and/or additional warrants to purchase up to 581,250 shares of common stock to cover over-allotments, if any.
More on The Arizonar
Roth Capital Partners is acting as sole manager for the offering.
The securities described above are being sold by the Company pursuant to a registration statement on Form S-1 (Registration No. 333-259834) that was previously filed by the Company with the Securities and Exchange Commission (the "SEC") and declared effective on December 2, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering is being made only by means of the written prospectus forming part of the effective registration statement. Electronic copies of the accompanying prospectus may be obtained, when available, by contacting Roth Capital Partners, 888 San Clemente, Newport Beach, CA 92660, Attn: Prospectus Department, telephone: 800-678-9147, or email at [email protected], or by visiting the SEC's website at http://www.sec.gov.
About Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company focused on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications. For further information about the company go to www.creativemedicaltechnology.com.
More on The Arizonar
Forward-Looking Statements
This press release contains "forward-looking statements" about the company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company's future performance include the company's ability to obtain additional capital to expand operations as planned, success in attracting additional customers, obtaining necessary regulatory approvals, enrollment of adequate numbers of patients in clinical trials, and unforeseen difficulties in showing efficacy of the company's products. These and other risk factors are described from time to time in the company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's recent registration statement on Form S-1 and reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.
www.creativemedicaltechnology.com
www.CaverStem.com
www.FemCelz.com
www.StemSpine.com
www.immcelz.com
SOURCE Creative Medical Technology Holdings, Inc.
As a result of the offering, the Company's common stock will become listed on the Nasdaq Capital Market and will trade under the ticker symbol "CELZ" beginning December 3, 2021. The offering is expected to close on or about December 7, 2021, subject to customary closing conditions. In addition, the Company has granted to the underwriters of the offering a 45-day option to purchase up to 581,250 additional shares and/or additional warrants to purchase up to 581,250 shares of common stock to cover over-allotments, if any.
More on The Arizonar
- Arizona: Water Infrastructure Finance Authority Board Applications Open
- Non-profit Responds to Post Covid Needs
- Eagan Immigration Announces Their Debut on the Inc. 5000
- City of Mesa Maintains Stage One Water Shortage Following U.S. Bureau of Reclamation Following August 24-Month Study
- The Stage is Set for The 2022 DLH Inspire Awards in Hollywood
Roth Capital Partners is acting as sole manager for the offering.
The securities described above are being sold by the Company pursuant to a registration statement on Form S-1 (Registration No. 333-259834) that was previously filed by the Company with the Securities and Exchange Commission (the "SEC") and declared effective on December 2, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering is being made only by means of the written prospectus forming part of the effective registration statement. Electronic copies of the accompanying prospectus may be obtained, when available, by contacting Roth Capital Partners, 888 San Clemente, Newport Beach, CA 92660, Attn: Prospectus Department, telephone: 800-678-9147, or email at [email protected], or by visiting the SEC's website at http://www.sec.gov.
About Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company focused on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications. For further information about the company go to www.creativemedicaltechnology.com.
More on The Arizonar
- Housing Choice Voucher Wait List Opening in Mesa
- Arizona: Governor Ducey, Parents, Kids Celebrate The Most Expansive School Choice Initiative In The Nation
- Contracting Resources Group, Inc. Named on Inc. 5000 List of Fastest-Growing Private Companies for Fifth Year
- Former Marine Sergeant Michael J. Rotch Launches Life Coaching Program, Helping People Find Their Voice
- Climate Justice Advocate, Felicia Davis, Statement on the Inflation Reduction Act
Forward-Looking Statements
This press release contains "forward-looking statements" about the company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company's future performance include the company's ability to obtain additional capital to expand operations as planned, success in attracting additional customers, obtaining necessary regulatory approvals, enrollment of adequate numbers of patients in clinical trials, and unforeseen difficulties in showing efficacy of the company's products. These and other risk factors are described from time to time in the company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's recent registration statement on Form S-1 and reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.
www.creativemedicaltechnology.com
www.CaverStem.com
www.FemCelz.com
www.StemSpine.com
www.immcelz.com
SOURCE Creative Medical Technology Holdings, Inc.
Filed Under: Business
0 Comments
Latest on The Arizonar
- The Alkaline Water Company Reports Record Revenue of $16.9 Million in First Quarter Fiscal Year 2023
- Bold New Book, If Only We Knew, Offers A Framework To Understand And Solve Today's Social Issues
- Living Waters Inc to Host the "2022 Mental Health Summit"
- University of Phoenix announces agreement with MedCerts that supports healthcare and IT learners with upskilling and pathway to degrees
- Wood Underwear® FW22 Introduces New Styles in Lounge
- Checkers® & Rally's® Kicks off First Half of 2022 with Strong Development Growth and Recognition
- Loxperts Inc. launches the first-ever on-demand freelancer marketplace dedicated to localization experts
- Journey Medical Corp Announces New Journey with the Experts Video Featuring Pantea Tamjidi, MD
- Agent Timothy Braue Awarded Prestigious "Premier Luxury Marketing Consultant" Certification
- Arizona: Governor Ducey Issues Executive Order To Fill Gaps in Border Wall
- University of Phoenix College of Doctoral Studies Releases Latest Edition of Its Phoenix ScholarTM Academic Journal Highlighting Research Based on Career Optimism Index® Study of the University's Career Institute®
- Why should I use a company for Air Duct Cleaning in NJ
- Let's Finally Meet The Man That Fronts The Grammy Nominated Artist "Special Request Ft Rey T."
- Mesa Mayor John Giles Presents Key to the City to Actor Troy Kotsur
- Federal Defendants Acquitted of Conspiracy to Possess and Possession of 279 Kilos of Cocaine
- State Route 24 to Bring Traffic Relief to Southeast Mesa
- Waffle Forest To Use Native Species To Reduce Plant-Produced Pollution
- University of Phoenix Hosts Educational Equity Webinar Expanding Conversation and Insights on Generational Differences in the Workplace
- State Route 24 to Bring Traffic Relief to Southeast Mesa
- CORRECTING and REPLACING Zoned Properties Reports Second Quarter 2022 Financial Results